« Back to Medicines list

Gaviscon Liquid - Peppermint Flavour

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/01/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 2/9/2014
print

Print ViewKeyword Search SmPC

Reckitt Benckiser Ireland Limited

Reckitt Benckiser Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Bonjela Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Bonjela Teething Gel Oromucosal Gel Active Ingredients Cetalkonium Chloride, Choline Salicylate
Medicine Name Dettol Antiseptic Disinfectant 4.8 % w/v Concentrate for Cutaneous Solution Active Ingredients Chloroxylenol
Medicine Name Disprin Direct 300mg Orodispersible Tablets Active Ingredients Aspirin
Medicine Name Disprin Extra Strength 500mg Effervescent Tablets Active Ingredients Acetylsalicylic Acid
Medicine Name Disprin Original 300mg Dispersible Tablets Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name E45 Cream Active Ingredients Anhydrous Lanolin, Light Liquid Paraffin, White Soft Paraffin
Medicine Name Fybogel Citrus Active Ingredients Ispaghula Husk
Medicine Name Fybogel Mebeverine Active Ingredients Ispaghula Husk, Mebeverine Hydochloride
Medicine Name Fybogel Orange 3.5g Granules Active Ingredients Ispaghula Husk
Medicine Name Gaviscon Advance Chewable Tablets Active Ingredients Potassium Bicarbonate, Sodium Alginate
Medicine Name Gaviscon Advance Oral Suspension Active Ingredients Potassium hydrogen carbonate, Sodium Alginate
Medicine Name Gaviscon Extra Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Liquid Sachets Peppermint Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Extra Oral Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Infant Active Ingredients Magnesium Alginate, Sodium Alginate
Medicine Name Gaviscon Liquid - Peppermint Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Liquid Aniseed Flavour Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Gaviscon Peppermint Chewable Tablets Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Hydrogen Carbonate
Medicine Name Gaviscon Suspension Active Ingredients Calcium Carbonate, Sodium Alginate, Sodium Bicarbonate
Medicine Name Hc45 Hydrocortisone Acetate 1% w/w Cream Active Ingredients Hydrocortisone Acetate
Medicine Name Lemsip Chesty Cough 50 mg/5 ml Oral Solution Active Ingredients Guaifenesin
Medicine Name Lemsip Cold & Flu Headcold 500mg Powder for Oral Solution Active Ingredients Paracetamol
Medicine Name Lemsip Cold & Flu Hot Lemon 500mg Powder for Oral Solution Active Ingredients Paracetamol
Medicine Name Lemsip Cold + Flu Headcold Active Ingredients Paracetamol
1 - 0 of 64 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 January 2020 PIL

Reasons for updating

  • New PIL for new product

Updated on 2 September 2014 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through general sale

Updated on 2 September 2014 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.2 - added information for special patient groups
Section 4.3 - added contraindications for hypersensitivity to the active substances or excipients
Section 4.4 - Added additional precautions
Section 4.5 - added a time interval between taking Gaviscon and other medicinal products
Section 4.6 - Change to the format of section and an update to the information for taking Gaviscon during pregnancy
Section 4.7 -  Editorial change
Section 4.8 - Update to layout of frequency of adverse events and addition of reporting of adverse reactions
Section 5.1 - addition of ATC code and pharacotherapeutic group
Section 10 - updated date of revision of the text

Updated on 2 September 2014 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 4.2 - added information for special patient groups
Section 4.3 - added contraindications for hypersensitivity to the active substances or excipients
Section 4.4 - Added additional precautions
Section 4.5 - added a time interval between taking Gaviscon and other medicinal products
Section 4.6 - Change to the format of section and an update to the information for taking Gaviscon during pregnancy
Section 4.7 -  Editorial change
Section 4.8 - Update to layout of frequency of adverse events and addition of reporting of adverse reactions
Section 5.1 - addition of ATC code and pharacotherapeutic group
Section 10 - updated date of revision of the text

Updated on 13 December 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

In section 4.4, added " Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions."

Updated on 13 December 2012 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Free text change information supplied by the pharmaceutical company

In section 4.4, added " Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions."

Updated on 10 December 2012 PIL

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 6.4, "do not refrigerate" has been added.
In section 10, the date of revision of the text has been updated to November 2012.

Updated on 10 December 2012 SmPC

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

In section 6.4, "do not refrigerate" has been added.
In section 10, the date of revision of the text has been updated to November 2012.

Updated on 15 May 2007 PIL

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Free text change information supplied by the pharmaceutical company

Section 4.8.  Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions.
 
Section 7.  Change of marketing authorisation holder address to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Updated on 15 May 2007 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.8.  Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions.
 
Section 7.  Change of marketing authorisation holder address to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Updated on 9 August 2006 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container

Legal category: Supply through general sale

Free text change information supplied by the pharmaceutical company

Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5.  Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.

Reduction in shelf-life from three years to two years in section 6.3

Updated on 9 August 2006 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container

Free text change information supplied by the pharmaceutical company

Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5.  Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.

Reduction in shelf-life from three years to two years in section 6.3

Updated on 1 July 2005 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration

Updated on 1 July 2005 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration

Legal category: Supply through general sale

Updated on 19 May 2005 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Supply through general sale

Updated on 19 May 2005 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 10 August 2004 PIL

Reasons for updating

  • New SPC for medicines.ie

Updated on 10 August 2004 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through general sale